Alx Oncology Holdings Inc. (ALXO)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
Here is how ALX Oncology Holdings Inc. (ALXO) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript
ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript
Alx Oncology Holdings Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 41,095 | $64,705.66 | $81,162.62 | $16,456.96 | 25.43% |
 Melissa Tiscareno Bradley & Co. Private Wealth Management LLC | 1,000 | $8,090 | $1,975 | -$6,115 | -75.59% |
| JG John Ginter Callan Family Office LLC | 22,419 | $15,404.32 | $43,604.95 | $28,200.63 | 183.07% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 6 | $12 | $11.76 | -$0.24 | -2% |
 Ashley Meredith Abel Hall, LLC | 12,598 | $5,229.22 | $25,384.97 | $20,155.75 | 385.44% |
Alx Oncology Holdings Inc. (ALXO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alx Oncology Holdings Inc. ever had a stock split?
Alx Oncology Holdings Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jason Lettmann CEO | NASDAQ (NGS) Exchange | 00166B105 CUSIP |
| US Country | 43 Employees | - Last Dividend | - Last Split | 17 Jul 2020 IPO Date |
Overview
ALX Oncology Holdings Inc. is a pioneering force within the field of immuno-oncology, primarily engaged in the development of innovative therapies aimed at enhancing the lives of cancer patients across the United States. Since its establishment in 2015, the company's efforts have been directed towards harnessing the power of the immune system to fight cancer more effectively. ALX Oncology is headquarted in South San Francisco, California, a hub renowned for its cutting-edge biotechnology research. With a keen focus on clinical-stage projects, the company is steadfast in its mission to achieve breakthroughs in cancer treatment.
Products and Services
ALX Oncology's pipeline is distinguished by its lead product candidate, Evorpacept, alongside a portfolio of promising clinical studies and collaborations designed to explore a broad spectrum of cancer treatments:
- Evorpacept: This flagship CD47 blocking therapeutic biologic is at the forefront of ALX Oncology's offerings. Designed to be used in combination with other anti-cancer agents, Evorpacept is involved in several key clinical studies targeting various types of cancer:
- ASPEN-06 (Phase 2) for Gastric/GEJ cancer.
- ASPEN-07 (Phase 1) for urothelial cancer.
- ASPEN-03 and ASPEN-04 (both Phase 2) for head and neck squamous cell carcinoma.
- Collaboration Agreements for Evorpacept Combination Programs: ALX Oncology's strategic collaborations amplify the potential of Evorpacept through a variety of combination programs targeting breast cancer, solid tumors, NHL, multiple myeloma, metastatic colorectal cancer, and recurrent platinum-resistant ovarian cancer with partners such as Jazz Pharmaceuticals plc, Quantum Leap Healthcare Collaborative, MD Anderson Cancer Center, Sanofi, the Academic Gastrointestinal Cancer Consortium, and the University of Pittsburgh.
- ALTA-002: In partnership with Tallac Therapeutics, Inc., ALX Oncology is developing this potent immune activator targeted to myeloid cells within the tumor microenvironment. The goal is to foster both innate and adaptive anti-cancer immune responses, marking a significant step towards innovative cancer immunotherapies.
- License Agreements: ALX Oncology's collaborative approach is further exemplified by its license agreements with several esteemed entities, including the Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. These agreements are pivotal in supplementing the company's robust research and development efforts.
